Metabolex Announces Positive Results From Phase 1a Clinical Trial o...(pyfor treating type 2 diabetes said Har...)

Date:11/12/2008

py for treating type 2 diabetes," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex. "Based on the excellent safety profile and encouraging effects on glucose levels observed in our Phase 1a trial, we have advanced MBX-2982 into a Phase 1b study in which we are evaluating the multiple-dose pharmacokinetics and pharmacodynamics."

"We are now focusing our earlier stage research and development programs on GPCR targets," stated Chuck McWherter, Senior Vice President of Research and Preclinical Development at Metabolex. "The positive results from our GPR119 program demonstrate the utility of this approach which emphasizes innovative GPCR-based strategies for the development of treatments for serious unmet medical needs."

About MBX-2982

MBX-2982 is an agonist of GPR119, a GPCR that is expressed in pancreatic islets and the gastrointestinal tract. Pre-clinical studies conducted by Metabolex and others show that GPR119 agonists can stimulate glucose-dependent insulin secretion and release of incretin hormones such as GLP-1, and thus may preserve beta cell health. This novel dual mechanism may provide a unique therapeutic benefit in the treatment of type 2 diabetes. Additionally, the stimulation of GLP-1 release may mimic the benefits of incretin analogues such as exenatide (a GLP-1 analogue marketed as Byetta(R)). Unlike exenatide, however, MBX-2982 can be delivered orally.

About Diabetes

Diabetes is a worldwide health problem and a rapidly growing source of illness, death and health care costs. According to the International Diabetes Federation, approximately 246 million adults, or 6 percent of the world's adult population, had diabetes in 2007. The American Diabetes Association (ADA) estimates that there were approximately 23.5 million adults in the United States with diabetes in 2007, making up 10.7 percent of the adult population. According to estimates from the ADA, one in ten health care dollars is attributed to diab
'/>"/>

SOURCE Metabolex Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Metabolex Appoints Donald Hill as Chief Financial Officer
2. Metabolex Names Zhao, Martin to Executive Posts
3. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter